Sep 2026· Food and Chemical Toxicology· pp.
116394
· 0 citations· 86 references
Medicine
Abstract
The continuous development of innovative food products has reinforced the importance of rigorous safety evaluations within the European Union (EU) novel food framework. Among toxicological endpoints, genotoxicity is a critical determinant, as substances with genotoxic potential relevant to humans raise safety concerns and are not accepted for intentional inclusion in the food chain. This review provides a historical overview of how genotoxicity has been addressed in scientific opinions adopted by the European Food Safety Authority (EFSA) in the context of novel food applications. The analysis demonstrates considerable variability in both the type and form of test items assessed and the genotoxicity strategies employed. While mostly standard in vitro test batteries were sufficient to rule out the genotoxicity concerns, specific scenarios required in vivo tests in order to rule out the risk. Over time, the implementation of updated EFSA guidance has contributed to greater consistency in study design and interpretation. In one case where genotoxicity concerns could not be adequately resolved, a favourable safety conclusion was not supported under any proposed use. By mapping regulatory precedents and decision-making patterns, this review offers practical insight into EFSA's evolving approach to genotoxicity assessment and provides guidance for applicants designing future testing strategies.
Abstract Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on cannabidiol (CBD) obtained by chemical synthesis as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF consists of ≥ 98% (w/w) CBD and is intended...
D. Turck, T. Bohn, Montaña Cámara et al.· EFSA journal. European Food...· 0 citations
The European Union's ban on in vivo genotoxicity testing for cosmetic ingredients (Directive 2003/15/EC), followed by the Scientific Committee on Consumer Safety (SCCS) 7th amendment, has created an urgent need for robust, non-animal genotoxicity testing strategies. Standard regulatory in vitro assays - including the A...
Yax Thakkar, D. Botelho, A. M. Api· Food and Chemical Toxicology· 0 citations
Abstract Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the safety of benfotiamine as a novel food (NF) pursuant to Regulation (EU) 2015/2283 and on the bioavailability of benfotiamine as a source of thiamin in the c...
D. Turck, T. Bohn, Montaña Cámara et al.· EFSA journal. European Food...· 0 citations
In April 2025, the US Food and Drug Administration (FDA) introduced a bold roadmap to phase out animal testing in drug development by promoting the integration of New Approach Methodologies (NAMs), beginning with monoclonal antibodies (mAbs). Similar roadmaps have also been created by European health authorities and ch...
N. Stokar-Regenscheit, B. Berridge, J. Kühnlenz et al.· Toxicologic pathology (Print...· 0 citations
Five key recommendations for future health risk assessments are concluded, prioritizing PFAS; improving analytical methods; promoting generation of robust data and data gap filling; promoting open science, including the development of shared data infrastructure and cross-institutional knowledge exchange; and strengthen...
J. Kowalczyk, Klaus Abraham, Christina August et al.· Archives of Toxicology· 0 citations
The evaluation of 28- and 90-day repeated-dose toxicity studies in rodents is typically performed at the highest tier of regulatory toxicology. Despite detailed guidance from the European Food Safety Authority (EFSA) and Organisation for Economic Co-operation and Development (OECD), the practical implementation and eva...
S. Favilla, Eugenio Traini, M. Ardizzone et al.· Regulatory toxicology and ph...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.